Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Afebryl
- Development stage
- Unknown
- Lead developer
- SMB Laboratoires
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Afebryl is an over-the-counter combination effervescent tablet containing acetylsalicylic acid (300 mg), paracetamol (200 mg), and ascorbic acid (300 mg). It is indicated for the symptomatic treatment of mild to moderate pain and fever, particularly during flu-like conditions and upper respiratory tract infections. Acetylsalicylic acid and paracetamol act as analgesics and antipyretics by inhibiting prostaglandin synthesis via cyclooxygenase (COX) pathways, while ascorbic acid (vitamin C) is included to support cellular oxidation-reduction reactions and prevent vitamin C deficiency during acute infections. Originally developed by Laboratoires SMB and marketed in Portugal by Laboratórios Azevedos, Afebryl is administered orally after being dissolved in water.
- Brand names
- Afebryl
- Other names
- Acetylsalicylic Acid + Paracetamol + Ascorbic AcidAcetylsalicylic Acid, Paracetamol, Ascorbic Acid
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on Afebryl.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Afebryl.